Continue to Site >>>

Melissa Vonder Haar

Freelance Writer...

Articles by
Melissa Vonder Haar

Page 5
CBD/Hemp

Could CBD Be Snatched From Traditional Retailers?

Drug and supplement companies come out strong during FDA hearings

CBD/Hemp

The FDA's CBD Hearing: Four Things to Watch

Pressing questions that will shape the future of this new category

CBD/Hemp

What’s the ‘Next’ CBD?

Three cannabinoids that everyone will be talking about soon

CBD/Hemp

6 Insights Into the Mind of the CBD Consumer

Study suggests opportunity for mainstream retailers and manufacturers

CBD/Hemp

4 Months After the Farm Bill, Which Channel Is Winning CBD?

Drugstores take an early lead, but convenience channel is primed to battle back

CBD/Hemp

Gottlieb Calls for Congress to Act on CBD

Legal experts weigh in on the likelihood of action in Washington

CBD/Hemp

CBD Regulatory Update: 1st Quarter 2019

A number of state and local governments look to limit the sale of CBD-infused products

CBD/Hemp

CBD a 'Hard Challenge' for Regulators: FDA Commissioner

Agency will create a working group and hold public hearings in April

CBD/Hemp

Will the FDA Clamp Down on CBD?

What the agency has said about regulating hemp products

CSP Magazine

Every Ad Counts

The FDA is rolling out two retailer-centric ad campaigns. Will it have an impact?

CSP Magazine

Burning Bright

With a new direction from the FDA and the rise of smoking alternatives, category optimism is on the upswing

Tobacco

FDA Committee Rejects iQOS Modified-Risk Claim

Regulators will review recommendation, consider PMI’s reduced-risk arguments

  • Page 5